Clinical Trial

Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is a multicenter, prospective, randomized phase II trial designed to observe and evaluate the efficacy and safety of trastuzumab, pertuzumab, docetaxel combined with QL1706 versus combined with carboplatin as neoadjuvant therapy in patients with operable or locally advanced HER2-positive breast cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-17.
Trial Details
NCT Number NCT07246317
Lead Sponsor Tianjin Medical University Cancer Institute and Hospital
Conditions Breast Cancer
Enrollment 188 participants
Start Date 2025-12-15
Primary Completion 2027-12-31 (estimated)
Study Completion 2032-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-11-28